REFERENCES
- Friesen, P., L. Gelinas, A. Kirby, D. H. Strauss, and B. E. Bierer. 2023. IRBs and the protection-inclusion dilemma: Finding a balance. The American Journal of Bioethics 23 (6):75–88. doi:10.1080/15265161.2022.2063434.
- Loree, J. M., S. Anand, A. Dasari, J. M. Unger, A. Gothwal, L. M. Ellis, G. Varadhachary, S. Kopetz, M. J. Overman, K. Raghav, et al. 2019. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncology 5 (10): E191870. doi:10.1001/jamaoncol.2019.1870.
- Mendis, S., S. Anand, J. M. Karasinska, A. Dasari, J. M. Unger, A. Gothwal, L. M. Ellis, G. Varadhachary, S. Kopetz, M. J. Overman, et al. 2021. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. The Oncologist 26 (2):107–14. doi:10.1002/onco.13534.
- Miller, J. E., M. M. Mello, J. D. Wallach, E. M. Gudbranson, B. Bohlig, J. S. Ross, C. P. Gross, and P. B. Bach. 2021. Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs. JAMA Network Open 4 (5):e217075. doi:10.1001/jamanetworkopen.2021.7075.
- Miller, J., and J. Millum. 2022. Ethical considerations in international clinical trial site selection. BMJ Global Health 7:e008012. doi:10.1136/bmjgh-2021-008012.
- Murthy, V. H., H. M. Krumholz, and C. P. Gross. 2004. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. Journal of American Medical Association 291 (22):2720–6. doi:10.1001/jama.291.22.2720.
- Ramachandran, R., J. S. Ross, and J. E. Miller. 2021. Access to COVID-19 vaccines in high-, middle-, and low-income countries hosting clinical trials. JAMA Network Open 4 (11):e2134233. doi:10.1001/jamanetworkopen.2021.34233pmid.
- Varma, T., C. P. Gross, and J. E. Miller. 2023. Clinical trial diversity—will we know it when we see it? JAMA Oncology. doi:10.1001/jamaoncol.2023.0143.
- Varma, T., M. Mello, J. S. Ross, C. Gross, and J. Miller. 2023. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: Retrospective cross sectional study. BMJ Medicine 2 (1):e000395. doi:10.1136/bmjmed-2022-000395.
- Varma, T., J. D. Wallach, J. E. Miller, D. Schnabel, J. J. Skydel, A. D. Zhang, M. A. Dinan, J. S. Ross, and C. P. Gross. 2021. Reporting of study participant demographic characteristics and demographic representation in premarketing and postmarketing studies of novel cancer therapeutics. JAMA Network Open 4 (4):e217063. doi:10.1001/jamanetworkopen.2021.7063pmid.